Meta‐analysis of mortality in patients with high‐risk intraductal papillary mucinous neoplasms under observation. BJS 2018; 105: 328-338.
Published: 6th February 2018
Authors: G. Vanella, S. Crippa, L. Archibugi, P. G. Arcidiacono, G. Delle Fave, M. Falconi et al.
Although consensus guidelines suggest that patients with high‐risk intraductal papillary mucinous neoplasms (IPMNs) should have surgery, a non‐operative strategy is often selected in patients who are poor surgical candidates. The aim was to determine the risk of disease‐related death from IPMN in patients with worrisome features or high‐risk stigmata who were kept under observation.
A PubMed literature search was undertaken of articles published from August 1992 to June 2016 (updated October 2017). The methodology was developed from PRISMA and MOOSE checklists. Incidence proportions and rates of overall and IPMN‐related deaths were calculated, with subgroup analyses for main‐duct/mixed‐type and branch‐duct IPMNs. Quality of the studies, publication bias and heterogeneity were explored.
Six studies reported data on overall mortality and eight described disease‐specific mortality for 556 patients during follow‐up ranging from 24·9 to 60·0 months. Pooled rates of overall and IPMN‐related mortality were 30·9 (95 per cent c.i. 19·6 to 45·1) and 11·6 (6·0 to 21·2) per cent respectively. The pooled incidence rate for overall mortality was substantially higher than that for IPMN‐related mortality: 78 (95 per cent c.i. 44 to 111) and 23 (9 to 37) per 1000 patient‐years respectively. The pooled incidence rate for disease‐specific mortality was considerably lower for branch‐duct than for main‐duct or mixed‐type IPMNs: 5 (0 to 10) and 32 (12 to 52) per 1000 patient‐years respectively.
In patients unfit for surgery, IPMN‐related mortality among patients with worrisome features and high‐risk stigmata is low, and the risk of death from other causes much higher.Full text
You may also be interested in
Authors: M. Del Chiaro, K. Søreide
Multicentre study of the prognostic impact of preoperative bodyweight on long‐term prognosis of hepatocellular carcinoma.
Authors: J. J. Yu, F. Shen, T. H. Chen, L. Liang, J. Han, H. Xing et al.
Notes: BMI matters
Authors: G. Marchegiani, S. Andrianello, G. Morbin, E. Secchettin, M. D'Onofrio, R. De Robertis et al.
Notes: Duct dilatation no risk alone
Pancreas‐sparing, ampulla‐preserving duodenectomy for major duodenal (D1–D2) perforations. BJS 2018; 105: 1487-1492.
Authors: S. Di Saverio, E. Segalini, A. Birindelli, S. Todero, M. Podda, A. Rizzuto et al.
Notes: Useful option
Profile of exhaled‐breath volatile organic compounds to diagnose pancreatic cancer. BJS 2018; 105: 1493-1500.
Authors: S. R. Markar, B. Brodie, S.‐T. Chin, A. Romano, D. Spalding, G. B. Hanna et al.
Notes: Breath test for pancreatic cancer
Authors: S. Gasteiger, B. Cardini, G. Göbel, R. Oberhuber, F. Messner, T. Resch et al.
Notes: Good outcome in selected patients
Meta‐analysis of the prognostic role of perioperative platelet count in posthepatectomy liver failure and mortality. BJS 2018; 105: 1254-1261.
Authors: A. Mehrabi, M. Golriz, E. Khajeh, O. Ghamarnejad, P. Probst, H. Fonouni et al.
Notes: Low platelets, worse outcomes
Meta‐analysis of prognostic factors for overall survival in patients with resected hilar cholangiocarcinoma. BJS 2018; 105: 1408-1416.
Authors: N. T. E. Bird, A. McKenna, J. Dodd, G. Poston, R. Jones, H. Malik et al.
Notes: Tumour biology is important
Randomized clinical trial
Randomized clinical trial of stapler hepatectomy versus LigaSure™ transection in elective hepatic resection. BJS 2018; 105: 1119-1127.
Authors: J. Fritzmann, J. Kirchberg, D. Sturm, A. B. Ulrich, P. Knebel, A. Mehrabi et al.
Authors: Y. Kishi, S. Nara, M. Esaki, N. Hiraoka, K. Shimada
Notes: Standardized lymphadenectomy is important
Neoadjuvant chemotherapy response influences outcomes in non‐colorectal, non‐neuroendocrine liver metastases.
Authors: A. M. Lucchese, A. N. Kalil, A. Ruiz, V. Karam, O. Ciacio, G. Pittau et al.
Notes: Multimodal therapy works
Authors: B. Groot Koerkamp, W. R. Jarnagin